There have been a number of groups affected by the pending MDL involving Zantac, the popular heartburn medication. It is alleged that the defendants knew that Zantac was hazardous to consumers for years, but it only became publicly known in September, 2019 when the...
Litigation Update: Elmiron MDL Sent to New Jersey
On Tuesday, December 15th the JPML sent all Elmiron cases to be tried in New Jersey by U.S. Judge Brian R. Martinotti. The judge had been handling Elmiron lawsuits and had already set up processes resembling those typically followed in MDLs. Because those efforts were...
Litigation Update: JPML to Decide on Elmiron’s Litigation Venue
At the last JPML hearing held on Thursday, December 4th, the panel heard from counsel for Johnson & Johnson and lawyers for plaintiffs. Both sides presented arguments for creating an MDL for all Elmiron cases in New Jersey federal court. Those proposing NJ as...
Litigation Update: FDA Denies Request to Add Birth Defect Warning to Zofran’s Label
The FDA has notified Novartis that it has rejected their request to add a birth defect warning to Zofran’s label. Plaintiffs claim that Zofran, a drug used to treat nausea for cancer and surgery patients, was also promoted by GlaxoSmithKline - the original developer...